Loading stock data…
SPRY
$8.56+0.30 (+3.63%)
Market ClosedLast close May 1
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ARS Pharmaceuticals, Inc. in the Healthcare sector is trading at $8.56. The stock is currently near its 52-week low of $6.66, remaining 19.0% below its 200-day moving average. Technical signals show neutral RSI of 61 and bullish MACD crossover, explaining why SPRY maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.56
Potential Upside
5%
Whystock Fair Value$8.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$26.71+212.1%
Range$12.00 – $34.00
Fundamentals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal deliv...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$834.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-149.92%
Volume
Today's trading volume
1.49M
Recent News
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?
ARS Pharmaceuticals, Inc. (SPRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. ARS Pharmaceuticals, Inc. is another best biotech stock under $10 to buy. TheFly reported on April 9 that Northland initiated coverage of SPRY with an Outperform rating and a $25 price target. The firm highlighted Neffy, a needle-free intranasal epinephrine […]
ARS Pharmaceuticals Q4 Earnings Call Highlights
ARS Pharmaceuticals (NASDAQ:SPRY) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline early commercial progress for neffy, its needle-free epinephrine option for Type I allergic reactions including anaphylaxis, while emphasizing that growth in the category has be
ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ...
ARS Pharmaceuticals Inc (SPRY) reports robust revenue growth and plans for sales force expansion amidst challenges in prescriber workflows and market penetration.
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -0.96% and +9.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?